Myriad Wields Proprietary Database To Protect Testing Market
This article was originally published in The Gray Sheet
Executive Summary
Myriad president Mark Capone made it clear that the company will use its proprietary database of genetic variants on the BRCA1 and BRCA2 genes to try and fend off cheaper competition after the BRACAnalysis test’s method patents are expired, or if they are overturned in court.